Blocking SARS-CoV-2 Delta variant (B.1.617.2) spike protein receptor-binding domain binding with the ACE2 receptor of the host cell and inhibiting virus infections using human host defense peptide-conjugated graphene quantum dots.

This research explores a new way to fight the highly contagious Delta variant of COVID-19, known as B.1.617.2. Scientists have discovered that certain human defense peptides-tiny proteins in our bodies designed to protect us from germs and viruses-can attach themselves directly onto a key part of this virus called the spike protein. This attachment is like putting on armor, making it harder for the Delta variant to enter cells where it can cause illness. To make these defense peptides even more effective at stopping infections, researchers have linked them with special nanoparticles made from graphene-a material that's strong and conductive but also safe enough to be used inside our bodies without causing harm or triggering an immune response. This combination has shown great promise by not only blocking the virus effectively on its own in lab tests, using human cells called HEK293T cell lines, but it could potentially lead to new treatments that help prevent people from getting sick with COVID-19 when they come into contact with this Delta variant.

The study conducted by researchers at Jackson State University and the American Type Culture Collection, in collaboration with Montan0 Molecular, aimed to investigate a novel approach for blocking SARS-CoV-2 Delta Variant (B.1.617.2) spike protein RBD binding using human host defense peptides conjugated graphene quantum dots (GQDs). The methodology involved synthesizing GQDs from natural Graphite powder and utilizing them as a platform to attach the HNP1(ACYCRIPACIAGERRYGTCIYQGRLW AFCC) peptide, known for its antimicrobial properties. The conjugated molecules were then tested against HEK293T cells expressing ACE2 receptors to evaluate their efficacy in blocking the spike protein-ACE2 interaction critical for viral entry into host cells.